Immunome Total Liab Over Time
| IMNM Stock | USD 8.57 0.21 2.51% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Immunome Performance and Immunome Correlation. Immunome |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunome. If investors know Immunome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunome listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (7.94) | Revenue Per Share | Quarterly Revenue Growth (0.18) | Return On Assets | Return On Equity |
The market value of Immunome is measured differently than its book value, which is the value of Immunome that is recorded on the company's balance sheet. Investors also form their own opinion of Immunome's value that differs from its market value or its book value, called intrinsic value, which is Immunome's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunome's market value can be influenced by many factors that don't directly affect Immunome's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunome's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunome is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunome's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Total Liab Analysis
Compare Immunome and related stocks such as Anebulo Pharmaceuticals, Adagene, and Acrivon Therapeutics, Total Liab Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ANEB | 3.2 M | 3.2 M | 3.2 M | 3.2 M | 3.2 M | 3.2 M | 3.2 M | 3.2 M | 3.2 M | 3.2 M | 241.6 K | 512.5 K | 1.1 M | 260.6 K | 234.5 K | 222.8 K |
| ADAG | 95.4 M | 95.4 M | 95.4 M | 95.4 M | 95.4 M | 95.4 M | 95.4 M | 95.4 M | 95.4 M | 162.9 M | 173.7 M | 33 M | 69.3 M | 45.2 M | 40.7 M | 77.3 M |
| ACRV | 10.6 M | 10.6 M | 10.6 M | 10.6 M | 10.6 M | 10.6 M | 10.6 M | 10.6 M | 10.6 M | 10.6 M | 10.6 M | 130.4 M | 10.8 M | 17.1 M | 15.4 M | 14.6 M |
| ANAB | 3.8 M | 3.8 M | 3.8 M | 3.8 M | 19.1 M | 13.9 M | 22.9 M | 21.8 M | 22.6 M | 30.2 M | 19.8 M | 286.6 M | 348.3 M | 364.3 M | 413 M | 433.6 M |
| MLYS | 5.1 M | 5.1 M | 5.1 M | 5.1 M | 5.1 M | 5.1 M | 5.1 M | 5.1 M | 5.1 M | 5.1 M | 5.1 M | 34 M | 166.7 M | 10.5 M | 14.6 M | 13.9 M |
| MOLN | 61.8 M | 61.8 M | 61.8 M | 61.8 M | 45.5 M | 67.6 M | 48.3 M | 27.7 M | 63.5 M | 50.8 M | 80.3 M | 65.4 M | 27.1 M | 21.9 M | 16.9 M | 16 M |
| MNOV | 325 K | 7.3 M | 4.7 M | 4.1 M | 5.3 M | 5.2 M | 5.3 M | 4.8 M | 4.1 M | 4.3 M | 4.1 M | 3.7 M | 3.9 M | 3.9 M | 3.4 M | 3.2 M |
| CSBR | 310 K | 12.2 M | 4.1 M | 5.7 M | 4 M | 5.5 M | 7.6 M | 8.1 M | 9 M | 15.4 M | 20.2 M | 26.3 M | 29.7 M | 28 M | 32.2 M | 33.9 M |
| AVTE | 7.2 M | 7.2 M | 7.2 M | 7.2 M | 7.2 M | 7.2 M | 7.2 M | 7.2 M | 7.2 M | 7.2 M | 18.1 M | 2.9 M | 8.6 M | 18 M | 20.7 M | 12 M |
| RZLT | 10.5 K | 10.5 K | 5.3 M | 997.9 K | 2.2 M | 2.1 M | 2.1 M | 6.5 M | 10.5 M | 3.6 M | 16.5 M | 2.9 M | 7.5 M | 11.7 M | 13.5 M | 14.2 M |
| ANTX | 887 K | 887 K | 887 K | 887 K | 887 K | 887 K | 887 K | 887 K | 887 K | 887 K | 24.6 M | 112.7 M | 7.2 M | 14 M | 16.1 M | 15.3 M |
| GANX | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 3.4 M | 4.2 M | 5.2 M | 6 M | 6.9 M | 4.4 M |
| INAB | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.5 M | 2.6 M | 4 M | 10.3 M | 8.8 M | 6.5 M | 5.5 M |
| LTRN | 651.6 K | 651.6 K | 651.6 K | 651.6 K | 651.6 K | 651.6 K | 651.6 K | 651.6 K | 651.6 K | 489.3 K | 660.8 K | 2.4 M | 2.8 M | 2.7 M | 3.2 M | 1.8 M |
| IKNA | 147.4 M | 147.4 M | 147.4 M | 147.4 M | 147.4 M | 147.4 M | 147.4 M | 147.4 M | 147.4 M | 147.4 M | 269.5 M | 40 M | 25.3 M | 22.3 M | 15.6 M | 14.8 M |
| CELC | 283.6 K | 283.6 K | 283.6 K | 283.6 K | 283.6 K | 283.6 K | 445.4 K | 578.1 K | 682.2 K | 983.2 K | 1.3 M | 17.2 M | 41.9 M | 51.5 M | 59.2 M | 62.1 M |
Immunome and related stocks such as Anebulo Pharmaceuticals, Adagene, and Acrivon Therapeutics, Total Liab description
The total amount of all liabilities that a company has, including both short-term and long-term liabilities.My Equities
My Current Equities and Potential Positions
| Immunome | IMNM |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Pennsylvania; U.S.A |
| Exchange | NASDAQ Exchange |
USD 8.57
Check out Immunome Performance and Immunome Correlation. To learn how to invest in Immunome Stock, please use our How to Invest in Immunome guide.You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Immunome technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.